Kornimate/medical-research-clean huggingface dataset:
determination of the validity of one-minute sit-to-stand test in obese and overweight children and adolescents

Conditions: Obese; Child Obesity; Adolescent Obesity; Exercise Capacity

Summary: obese individuals need to be evaluated comprehensively before exercise programs are determined. determination of exercise intolerance is important for the detection of functional limitations. one minute sit to stand test (1mstst) can be used as an alternative to cardiopulmonary exercise tests (cpet) or field tests. it is easy to use, quick to apply, valid and reliable, and applicable even in small areas. in addition, it is a simple assessment adequate for children's needs and behaviors and can be easily applied both in the clinic and at home, making it easier to use in children. studies have shown that 1mstst is a valid test in chronic obstructive pulmonary disease (copd), cystic fibrosis, interstitial lung disease, and, healthy children and adolescents. however, no study has been found regarding the validity of its use in obese children and adolescents.the aim of our study is to investigate the validity and reliability of 1mstst in overweight-obese children and adolescents.


Eligibility criteria:
inclusion criteria: * being in the 8-18 age range. * being overweight (between 85 and 95 according to the body mass index percentile). * being obese (over 95 based on the body mass index percentile). * not doing any vigorous exercise two hours before the test. exclusion criteria: * history of hospitalization in the last month for a reason that may affect physical performance. * having neurological, musculoskeletal disease that prevents exercise tests. * uncontrollable medical conditions (cardiovascular, pulmonary disease, etc.). * visual and/or vestibular disorders.

Keywords: obese patient functional test reliability validity
swift, certain, and fair: reducing recidivism and improving outcomes for alcohol and drug users on state parole

Conditions: Substance Abuse; Criminal Behavior

Summary: this research project will study the outcomes of medium- to high-risk parolees with a history of substance abuse in alleghany county, pennsylvania supervised under swift-certain-fair parole. the research goals are to: * determine the effectiveness of scf parole in reducing recidivism among medium- to high-risk parolees with a history of substance abuse in pennsylvania. * determine the minimum effective sanction in response to a violation that will bring parolees into compliance with the conditions of their parole.


Eligibility criteria:
inclusion criteria: * assigned to the pittsburgh district * allegheny county resident * has at least 2 years left on supervision * had a prior drug or alcohol related sanction exclusion criteria: * sex offender * reentrants assigned to the special needs unit
assessment of the effectiveness and tolerability of ovarian hyperstimulation

Conditions: STERILITY

Summary: the aim of the study is to assess the effectiveness of 5 mixed protocols of ovarian hyperstimulation with urinary gonadotrophins to achieve clinical pregnancy in females undergoing assisted reproductive techniques (ivf/icsi) (in-vitro fertilisation/intracytoplasmic sperm injection). study hypothesis: mixed protocols with urinary fsh (follicle-stimulating hormone) and urinary hmg (human menopausal gonadotropin)should be more effective than monotherapy.


Eligibility criteria:
inclusion criteria: * body mass index (bmi) between 18 and 30 * prolactin within the laboratory normal range * couples affected by sterility able to treat by ivf/icsi (in-vitro fertilisation/intracytoplasmic sperm injection) * patients undergoing menopur® and/or bravelle® treatment * normal thyroid function * women not receiving clomifen citrate or gonadotrophins within one month prior study start * couples willing to participate in the study that have signed the informed consent form exclusion criteria: * failure in 3 previous cycles of assisted reproduction ivf/icsi (in-vitro fertilisation/intracytoplasmic sperm injection) * policystic ovarian syndrome * seminal samples not apt for ivf-icsi (according to the criteria of each center) * evidence of significant bacterial infection in the seminogram of the couple in the preceding 6 months * antecedents of severe ovarian hyperstimulation syndrome (ohss) * important systemic disease * pregnancy or contraindication to pregnancy
certoparin in renal patients undergoing hemodialysis

Conditions: Renal Dialysis

Summary: this study will assess the efficacy, safety and pharmacokinetics of certoparin when used to prevent clotting during hemodialysis.


Eligibility criteria:
inclusion criteria: * patients requiring hemodialysis * patients requiring anticoagulation therapy during hemodialysis * written informed consent exclusion criteria: * hypersensitivity to study medication * genetic abnormality or disease of clotting system * prior major surgery or bleeding * other protocol-defined inclusion/exclusion criteria may apply

Keywords: hemodialysis, certoparin
one research on improving cognitive impairment caused by hypertension

Conditions: Hypertension

Summary: using the therapy of early intervention with qianyang yuyin granules to improve cognitive impairment caused by hypertension.

using the therapy of early intervention with qianyang yuyin granules to improve cognitive impairment caused by hypertension. the investigators designed a multi-center randomized controlled clinical trial to study the security and effectiveness of this therapy.

Eligibility criteria:
inclusion criteria: * aged 55 to 75 years old, male or female; * having a history of hypertension for more than 2 years but can maintain sbp ≤ 140 mmhg and bdp ≤ 90 mmhg with medication； * 21 ≤ mmse \< 26, or 14 ≤ moca \< 26, cdr \< 0.5. bseides, the chief complaint must happen after having hypertension； * meet tcm syndrome differentiation standard：according to the guidelines for the clinical research of chinese medicine new drugs ( published by china medical science press ) ：overabundant liver-fire type：dizziness and headache, both face and eyes are red, dry mouth and bitter taste in mouth, red tongue with yellowish coating, wire and frequent pulse. yin deficiency and yang hyperactivity type: dizziness and headache, tinnitus and forgetfulness, sphoria with feverish sensation in chest \& palms \& soles, palpitation and insomnia, red tongue \& thin white or less coating, wiry weak and numbered pulse； * ctmri hint: leukoaraiosis and no sign of cerebral infarction； * patients or the guardian hold the right opinions over the research and are willing to obey researcher's orders； * having a certain degree of education (being able to read simple newspapers in the past)； * patients agree to sign informed consent。 exclusion criteria: * secondary hypertension； * taking certain kinds of antihypertensive drugs which may damage brain cognitive function； * diagnosed as depression or other mental disorders according to dsm-iv； * diagnosed as vascular dementia according to diagnostic criteria, cdr ≥ 0.5; alzheimer disease or dementia caused by some other reasons (including mixed dementia according to diagnostic criteria for vci); cognitive impairment due to head injury。 * suffering from certain kinds of diseases which may interfere the assessment of cognitive function, including those who are diagnosed as alcoholics and drugs or psychotropic medicine abusers during the last 5 years according to dsm-iv； * accompanied with severe neurological function disorder； * asthma, chronic severe primary cardiovascular disease, liver lesion, hematological lesions, lung diseases, diabetes or other severe diseases may influence the patients' survival such as cancer or aids； * other: such as poor compliance, or can not attend the follow-up visit in time for some reasons； * taking the same kind of medicine during the last 30 days which may influence the trial； * is participating in another clinical study； * not up to tcm syndrome differentiation standard。

Keywords: safety effectiveness therapy qianyang yuyin granules cognitive impairment hypertension
pilot open label use of the hi-oxsr for the treatment of post covid-19 cognitive dysfunction

Conditions: Post COVID-19 Condition

Summary: during the worldwide covid-19 pandemic a large number patients reported different functional complaints one month or later after recovery from the acute infection. this entity had a number of names including "long-covid" or "post covid condition". long-covid is on the rise and no effective treatment exists yet to improve cognitive function. recent research has shown that people with even mild covid had a greater decline in executive function, notably in their ability to perform complex tasks. what drives post-covid cognitive changes is still a mystery and there are no effective treatments available. one hypothesis is that there is persistent immune activation resulting in reduction in cerebral blood flow. there is evidence that increased co2 may decrease inflammation, and decreased co2 may increase inflammation. objectives: the primary objective of this pilot study is to assess the safety and tolerability of the use of hi-ox sequential rebreathing for the treatment of post-covid cognitive dysfunction. the secondary objective is to identify the effects of the use of the hi-ox rebreathing treatment in changing post-covid cognitive dysfunction.


Eligibility criteria:
inclusion criteria: 1. ability to provide written informed consent. 2. previously diagnosed with cognitive dysfunction following recovery from covid. 3. not pregnant at time of study. 4. oxygen saturation on room air ≥92% at screening. 5. willing and able to comply with the treatment schedule and procedures. exclusion criteria: 1. history of cognitive dysfunction prior to covid infection 2. hospitalization for the treatment of covid 3. participating in another investigational trial or the use of an investigational drug within 30 days of screening 4. for individuals of childbearing potential: positive pregnancy test at screening or lactating or unwilling to practice a medically acceptable form of contraception from screening to day 14 (acceptable forms of contraception: abstinence, hormonal birth control, intrauterine device, or barrier method plus a spermicidal agent) 5. history of pulmonary hypertension 6. history of narcolepsy 7. moderate to severe copd 8. interstitial pulmonary fibrosis 9. end-tidal pco2 \>55 mmhg during training treatment 10. presence of a condition or abnormality that in the opinion of the investigator would compromise the safety of the subject or the quality of the data

Keywords: cognitive dysfunction post-covid condition long covid sars-cov2
injection molding technique: a minimally invasive management for enamel hypoplasia affecting permanent anterior teeth in children

Conditions: Enamel Hypoplasia

Summary: this study aims to evaluate and compare the clinical performance of the injectable giomer restoration versus an injectable composite resin restoration using the injection molding technique for veneering hypoplastic permanent maxillary and mandibular anterior teeth using the fdi criteria. follow up will be done every 6 months for 2 years.

the aim of this study is to evaluate and compare the two-year clinical performance of injectable giomer restoration to an injectable composite resin restoration using the injection molding technique for veneering permanent maxillary and mandibular anterior teeth affected with enamel hypoplasia in children using the fdi criteria. injection molding technique using injectable composite resin restoration and injectable giomer restoration will be implemented for the esthetic management of permanent anterior teeth affected with enamel hypoplasia in children after removal of the defective enamel, its etching and bonding. evaluation of their performance will be done using fdi criteria and will be followed up for 2 years.

Eligibility criteria:
inclusion criteria: * healthy patients: class i according to the american society of anaesthesiologists (asa class i). * teeth scored code 3 according to modified developmental defects of enamel (mdde) index. * maxillary and mandibular permanent anterior teeth exclusion criteria: * refusal of the parents to sign the informed consent. * signs and symptoms of reversible or irreversible pulpitis, as well as necrosis affecting the permanent anterior teeth. * enamel hypomineralization

Keywords: composite resin restoration giomer injectable restorations injection molding developmental enamel defects permanent anterior teeth
diclofenac potassium on ianb efficacy in symptomatic irreversible pulpitis

Conditions: Irreversible Pulpitis

Summary: the aim of this clinical trial is to evaluate the effect of pre-operative administration of diclofenac potassium on the efficacy of inferior alveolar nerve block on using 2% mepivacaine anaesthetic agent in patients with symptomatic irreversible pulpitis.

objective: the aim of this clinical trial is to evaluate the effect of pre-operative administration of diclofenac potassium on the efficacy of inferior alveolar nerve block on using 2% mepivacaine anaesthetic agent in patients with symptomatic irreversible pulpitis. design: randomized double-blind controlled trial. setting and conduct: * patients source: out patients of the clinic of endodontics at the faculty of oral and dental medicine, cairo university. * patients will be clinically and radiographically examined and their eligibility will be assessed and preoperative pain will be measured. eligible patients will be treated in one visit. * patients will be randomly assigned to one of 2 groups: experimental group (taking a 50 mg diclofenac potassium packet) and the control group (taking a placebo packet). each packet will be taken 30 minutes before starting treatment. the patient's pain will be assessed before local anesthetic administration using heft- parker visual analog scale (hp- vas). . after 15 minutes of the initial inferior alveolar nerve block (ianb) of 1.8 ml of 2% mepivacaine hydrochloride with 1:100000 epinephrine, the teeth will be examined using a cold pulp sensitivity test; in case of lip numbness together with no or mild pain on cold, the treatment will be initiated. * during root canal treatment, no to mild pain response on hp- vas will be considered success. in case of failure, supplemental anesthesia will be administered. * main outcome measures: anesthetic success during root canal treatment using hp vas.

Eligibility criteria:
inclusion criteria: 1. patients in good health as determined by a medical history and oral questioning. (asa i or ii) 2. age range is between 18 and 50 years. 3. patients having symptomatic irreversible pulpitis in one of their mandibular molars. 4. patients who can understand heft parker visual analogue scales vas. 5. patients accepting to participate in the study and able to sign informed consent. exclusion criteria: 1. pregnant female patient. 2. patients allergic to diclofenac potassium or mepivacaine. 3. patients having active pain in more than one mandibular molar. 4. patients who had taken analgesics in the 12 hours preceding the injection.

Keywords: anesthetic efficacy diclofenac irreversible pulpitis
alzheimer's disease core center

Conditions: Alzheimer's Disease; Mild Cognitive Impairment; Age-Related Memory Disorders

Summary: the main objective of this research project is to provide a comprehensive clinical database of patients with alzheimer's disease (ad) and other forms of dementia, individuals with mild cognitive impairment (mci), and age-matched normal controls. the study will also attempt to identify cognitively normal individuals at genetically defined risk for alzheimer's disease through genetic screening. all participants are seen annually. autopsies to establish diagnoses in patients with dementia, patients with mild mci, and cognitively normal elderly control subjects will also be conducted.

all participants are seen annually. in addition to a detailed neurological examination, participants will receive a standardized battery of neuropsychological tests and will undergo genetic testing. the investigators will provide standardized periodic longitudinal assessment of the research participants. autopsies to establish neurohistopathological diagnoses in clinically well-characterized patients with dementia, patients with mild mci, and cognitively normal elderly control subjects will also be conducted.

Eligibility criteria:
inclusion criteria: for patients with mci, or dementia, the presence of cognitive deficits including memory, language, and executive function. exclusion criteria: presence of non-neurological medical conditions interfering with cognition.

Keywords: alzheimer's dementia mild cognitive impairment
genome-wide association study of pituitary tumors

Conditions: Pituitary Adenomas

Summary: pituitary adenomas is a very common disease, but the cause and genetics hasn't been identified. the investigators are going to use genome-wide association study to identify genes that may be related to pituitary adenomas.


Eligibility criteria:
inclusion criteria: * patients diagnosed with pituitary adenomas exclusion criteria: * patients with a family history of endocrine tumors
impact of tiotropium add-on therapy in patients with asthma

Conditions: Asthma

Summary: to evaluate the effectiveness of add on therapy with tiotropium respimat® compared to increasing the dose of ics in patients with a diagnosis of asthma and on ics/laba therapy


Eligibility criteria:
inclusion criteria: * patients with least one asthma diagnosis in the inpatient setting or at least two separate instances of asthma diagnosis (separated by at least 30 days) recorded in the outpatient or emergency room setting will be included. * patients will be required to be already on inhaled corticosteroid/long-acting beta-agonist (ics/laba). * patients will be required to have available records 12 months prior to the index date. exclusion criteria: * patients below the age of 6 years on the inhaled corticosteroid/long-acting beta-agonist initiation (ics/labai) date will be excluded. * patients with a diagnosis of copd at any time during the study period will be excluded. * those who are on biologics at baseline will be removed. * after the psm process, unmatched patients will be excluded.
safety and efficacy study of q301 in mild to moderate adolescents and adults atopic dermatitis patients

Conditions: Atopic Dermatitis

Summary: this is a randomized, double-blind, vehicle-controlled, parallel-group comparison study to evaluate the safety and efficacy of q301 cream vs. vehicle in adolescent and adult subjects with mild to moderate ad. study drug (q301 cream or vehicle) will be administered topically twice a day for 8 consecutive weeks.


Eligibility criteria:
inclusion criteria: * patient, for a period of at least three months, has had a clinical diagnosis of ad according to the hanifin and rajka criteria by a board certified/eligible dermatologist. * patient has an investigator's global assessment (iga) score of 2 or 3 corresponding to mild or moderate ad * patient is in good general health and free of any disease state or physical condition that might impair evaluation of ad or which, in the investigator's opinion, exposes the patient to an unacceptable risk by study participation. exclusion criteria: * patient has used within four weeks prior to randomization, systemic treatment with: 1) corticosteroids, 2) cyclosporine, 3) other immunosuppressive treatment or any medication known to affect ad (e.g., jak inhibitors, etc.).
evaluate the effectiveness and safety of dpcp ointment (samcyprone™) on the clearance of verruca vulgaris (common warts)

Conditions: Common Warts; HPV (Human Papillomavirus); Periungual Warts; Plantar Warts

Summary: warts are benign epidermal tumors caused by human papillomaviruses (hpvs). the active pharmaceutical ingredient dpcp has been used for many years as a compounded formulation in acetone for the treatment of warts, alopecia areata and more recently, cutaneous metastatic melanoma lesions. an improved topical ointment formulation of dpcp called samcyprone™ will be evaluated for the treatment of common warts.


Eligibility criteria:
inclusion criteria: * male and female subjects between the ages of 18 and 65 years of age, inclusive * subjects presenting with at least one verruca vulgaris (common cutaneous, plantar, and periungual) warts for at least 4 weeks, but no more than 3 years * subject's common warts for treatment must measure between 3 and 20 mm and be located on hands, feet, limbs and/or trunk. a maximum of four (4) cutaneous single warts or one (1) area of clustered or adjacent warts up to 80 mm will be treated exclusion criteria: * genital warts may not be selected as target warts * subjects that are immuno-compromised * presence of systemic or localized diseases, conditions, or medications that could interfere with assessment of safety and efficacy or that compromise immune function

Keywords: hpv verruca vulgaris
clinical effect of cross titration of antipsychotics with ziprasidone in schizophrenia or schizoaffective disorder

Conditions: Schizophrenia; Psychotic Disorders

Summary: the primary objective is to compare effectiveness of ziprasidone treatment to current treatments (haloperidol, olanzapine or risperidone) measured by change in brief psychiatric rating scale (bprs) scores versus baseline


Eligibility criteria:
inclusion criteria: * primary diagnosis of schizophrenia or schizoaffective disorder, using dsm-iv criteria. * currently receiving either haloperidol, olanzapine or risperidone within -/+ 25% of the recommended daily dose (as delineated by the medication's package insert exclusion criteria: * resistance to conventional antipsychotic drugs * with antipsychotic agents other than olanzapine, risperidone or haloperidol at start of treatment regimen within 12 hours prior to first dose of study drug